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ABSTRACT
Introduction The massive scale- up of long- lasting insecticidal 
nets (LLINs) has led to major reductions in malaria burden 
in many sub- Saharan African countries. This progress is 
threatened by widespread insecticide resistance among 
malaria vectors. This cluster- randomised controlled trial 
(c- RCT) compares three of the most promising dual active 
ingredients LLINs (dual- AI LLINs), which incorporate mixtures 
of insecticides or insecticide synergists to standard LLINs in an 
area of pyrethroid insecticide resistance.
Methods A four- arm, single- blinded, c- RCT will evaluate the 
effectiveness of three types of dual- AI LLINs (1) Royal Guard, 
combining two insecticides, pyriproxyfen and the pyrethroid 
alpha- cypermethrin; (2) Interceptor G2, combining chlorfenapyr 
and alpha- cypermethrin; (3) Olyset Plus, an LLIN combining a 
synergist, piperonyl butoxide and the pyrethroid permethrin, 
compared with; (4) Interceptor LN, a standard LLIN containing 
the pyrethroid alpha- cypermethrin as the sole AI. The primary 
outcomes are malaria infection prevalence in children aged 
6 months–14 years and entomological inoculation rate (EIR), 
as a standard measure of malaria transmission at 24 months 
postintervention and cost- effectiveness.
Ethics and dissemination Ethical approval was received 
from the institutional review boards of the Tanzanian 
National Institute for Medical Research, Kilimanjaro Christian 
Medical University College, London School of Hygiene and 
Tropical Medicine, and University of Ottawa. Study findings 
will be actively disseminated via reports and presentations 
to stakeholders, local community leaders, and relevant 
national and international policy makers as well as through 
conferences, and peer- reviewed publications.
Trial registration number NCT03554616.
Strengths and limitations of this study
 ► This study is the first randomised controlled trial 
(RCT) to evaluate and compare the effectiveness 
of the next generation of dual- treated long- lasting 
insecticidal nets (LLINs), Royal Guard (a pyrethoid- 
pyriproxifen LLIN) and Interceptor G2 (a pyrethroid- 
chlorfenapyr LLIN) against standard LLIN to prevent 
malaria infection prevalence and incidence in an 
area of pyrethroid insecticide resistance.
 ► Results of this study will be presented to the WHO 
for policy recommendations and depending on the 
study outcomes has the potential to shape malaria 
vector control strategies across sub- Saharan Africa 
for the next decade.
 ► This is the second RCT to evaluate the new class 
of pyrethroid- piperonyl butoxide LLINs (Olyset Plus) 
in the Great Lakes Zone of Tanzania, expanding the 
evidence basis for deployment of this intervention 
class in areas of pyrethroid resistance.
 ► The trialling of the three main categories of dual 
active ingredients LLIN against the standard py-
rethroid LLIN in the same human cultural com-
munity against the same vector complex should 
offer the best opportunity to unravel relative ef-
fectiveness on malaria and effect on selection of 
insecticide resistance.
 ► Some limitations include the size of the cluster 
buffer areas, which might not prevent all con-
tamination between intervention arms, and the 
use of malaria rapid diagnostic tests (mRDT) to 
assess malaria infections rather than double- 
read blood slides, which may be more sensitive.
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INTRODUCTION
Long- lasting insecticidal nets (LLINs) are the primary 
method of malaria control in sub- Saharan Africa. The 
WHO estimates that over 50% of the population of sub- 
Saharan Africa now sleep under LLINs.1 Together with 
improved diagnosis and treatment, LLINs have helped 
reduce malaria incidence by 42% and mortality by 66% 
in Africa in the last 15 years.1 Pyrethroids are the only 
class of insecticide used routinely on LLINs, so the rapid 
spread of pyrethroid resistance across vector populations 
threatens to reverse the successes achieved so far, and 
may be a factor contributing to the current stagnation in 
malaria disease burden.2
Several studies have demonstrated that LLINs are 
becoming less effective at killing mosquitoes in areas of 
moderate to high pyrethroid resistance compared with 
those with susceptible vector populations.3–8 The search 
for new insecticides suitable for LLIN treatment is vital to 
sustain effective malaria vector control.
During the last decade, the WHO has encouraged 
manufacturers to develop new types of bed nets to control 
resistant mosquitoes. The chemical industry responded 
initially by developing a dual active ingredients LLIN 
(dual- AI LLIN), combining a pyrethroid insecticide with 
the synergist piperonyl butoxide (PBO), which inhibits 
cytochrome P450 oxidases (CYP) responsible for pyre-
throid resistance. Pyrethroid- PBO LLINs (py- PBO LLINs) 
have been available since 2009,9 but had only been recom-
mended by WHO for limited deployment until10 a recent 
cluster- randomised controlled trial (RCT) demonstrated 
a 44% reduction in malaria infection prevalence in chil-
dren in the py- PBO LLIN arm (Olyset Plus) compared 
with the standard pyrethroid LLIN (s- LLIN) after 2 
years.8 In 2017, based on this study, the WHO recognised 
the public health value of this new class of LLIN and 
recommended their scale up in area with pyrethroid resis-
tance.11 A second large- scale RCT in Uganda confirmed 
the superior protection of py- PBO LLIN against malaria 
compared with s- LLINs.12
Other manufacturers have responded to the WHO call 
by producing a different kind of dual- AI LLIN that incor-
porates a mixture of insecticides from different insec-
ticide classes. Mixtures of two insecticides on the same 
LLIN with differing modes of action have the potential to 
delay the evolution of resistance and extend the lifespan 
of both active ingredients on the LLIN. The two latest 
products are a pyrethroid- pyriproxyfen LLIN (py- PPF 
LLIN: Olyset Duo and Royal Guard) and a pyrethroid- 
chlorfenapyr LLIN (py- CFP LLIN: Interceptor G2). Both 
types of product have shown superior efficacy compared 
with s- LLINs in small- scale experimental hut trials.13–20 
The Py- PPF LLINs have demonstrated enhanced efficacy 
vector oviposition suppression and up to 95% reduction 
in vector reproductive rate in Benin.14 21 In addition, 
Py- PPF LLIN Olyset Duo, when compared with s- LLINs 
in an RCT in Burkina Faso, had a significantly greater 
impact on clinical malaria.22 The py- CFP LLIN, when 
compared with s- LLINs, has shown enhanced efficacy 
through higher killing against resistant mosquito species 
in experimental hut trials, producing mortalities with 
Anopheles gambiae s.l. of 71% versus 20% in Benin20 and 
78% versus 17% in Burkina Faso,18 and 71% versus 45% 
with Anopheles arabiensis23 and 70% versus 37% with Anoph-
eles funestus s.l. in Tanzania.24 Neither of these new AIs, 
pyriproxifen or chlorfenapyr, are related to one another 
nor show cross resistance. However, to receive a WHO 
public health recommendation, these ‘next- generation’ 
LLINs still need to be evaluated in two RCT25 to demon-
strate their effectiveness against malaria in human popu-
lations in areas characterised by different insecticide 
resistance intensities and major vector species.
In Tanzania, insecticide resistance has spread rapidly.26–28 
In regions where resistance is particularly strong, such as 
North- West Tanzania, the prevalence of malaria infection 
remains high (40% in children under 5 years old), despite 
universal coverage of s- LLINs.29 This finding echoes reports 
from Uganda, where no reduction in malaria incidence was 
observed after the distribution of s- LLINs.30 As operational 
failure of standard nets is occurring more frequently in areas 
with pyrethroid resistance, including the Great Lakes Zone,30 
the newly developed ‘next- generation’ LLINs now require 
urgent comparative evaluation.
Here, we describe the study design and methodology of an 
RCT, assessing the effectiveness and cost- effectiveness of three 
novel vector control interventions (dual- AI LLINs incorpo-
rating mixtures of insecticide classes or insecticide synergists), 
compared with the standard best practice of pyrethroid- only 
LLINs, to prevent malaria in an area of pyrethroid resistance 
in Tanzania. Each putative new class needs to show high effec-
tiveness versus the s- LLIN. None should select for stronger 
resistance to pyrethroid. Ideally, none should select for resis-
tance to the other new classes of dual- AI LLIN being tested. 
A four- arm trial is a highly efficient design, should demon-
strate the relative effectiveness of each against malaria, and 
the merits of each product against the same fauna of vector 
species and human cultural group. The trial should provide 
insight into future rotational strategies of deployment, their 
potential to manage insecticide resistance while controlling 
malaria.
The durability and bio- efficacy of the dual- AI LLIN are 
also being evaluated as per WHO guidelines31 and will be 
presented in a separate protocol, published elsewhere. The 
study protocol is reported in line with the Standard Protocol 
Items: Recommendations for Interventional Trials 2013 
statement.32
STUDY OBJECTIVES
The primary clinical and entomological objectives are to 
assess the effectiveness of py- PPF- LLINs, py- CFP- LLINs and 
py- PBO- LLINs compared with s- LLINs:
 ► On malaria infection prevalence in children from 6 
months–14 years over 2 years postintervention.
 ► On the entomological inoculation rate (EIR) of 
malaria vectors collected indoors over 2 years post 
intervention.
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The primary economic objective is to assess the cost- 
effectiveness of py- PPF- LNs, py- CFP- LNs, py- PBO- LNs and 
s- LLINs relative to one another.
All secondary objectives are detailed in figure 1.
METHODS AND ANALYSIS
Study setting
Five potential study sites in Tanzania’s Victoria lake 
zone were evaluated based on four criteria: report of a 
minimum of 30% malaria infection prevalence in total 
population, A. gambiae sensu stricto (s.s.) or A. funestus s.s. 
as the main vectors, insecticide pyrethroid resistance in 
standard WHO bioassays (<50% mortality), and no indoor 
residual spraying (IRS) planned for the next 3 years. Data 
from published and unpublished sources (including the 
National Malaria Control Programme, NMCP; and the 
President’s Malaria Initiative, PMI) were examined and 
complemented with data collection in November 2017, as 
appropriate. Only the district of Misungwi (2°51′00.0″S, 
33°04′60.0″E), on the southern border of Lake Victoria 
in Tanzania met all the criteria.
Misungwi covers an area of 2122 km2 and includes 27 
wards, 78 villages and a population of 351 607 people.33 
Average altitude in the study area is 1150 m. The annual 
rainfall ranges from 0.5 mm to 58.8 mm, split in two 
rainy seasons (October to December and March to May) 
and interrupted by a distinct long dry season (June to 
August/September) and a second short dry season in late 
December to February.34
Misungwi has moderate to high malaria transmission. In 
a study conducted in 2010, prevalence was 52% across all 
age groups.35 During the preliminary assessment in May 
2018, presence of all main Tanzanian malaria vectors, A. 
gambiae s.s., A. arabiensis and A. funestus s.s., were found 
in the area (unpublished data). WHO insecticide resis-
tance tests were also performed and 24- hour mortality 
in wild caught A. gambiae s.s. exposed to permethrin and 
deltamethrin was 7% and 19%, respectively. There was 
also evidence of pyrethroid resistance in A. funestus s.s. 
(mortality 50%) and A. arabiensis (mortality 65.3%). Pyre-
throid insecticide resistance has also been observed in the 
adjacent district of Magu and other lake zone regions, 
such as Geita and Kagera.28
The main vector control interventions in Misungwi are 
universal coverage of LLINs and IRS. The last distribution 
of LLINs and IRS campaign using Actellic 300CS were 
carried out in Misungwi district in 2015. In 2017, larvi-
ciding was done in some parts of the district.36 The district 
is also following national malaria control measures such 
as intermittent preventive treatment of malaria in preg-
nant women.
Study design
An overview of the trial design is given in figure 2. The 
design is a four parallel- arm, single- blind, superiority 
Figure 1 Secondary objectives. Dual- AI- LLINs, dual active ingredients LLINs; EIR, entomological inoculation rate; LLINs, long- 
lasting insecticidal nets; py- PBO- LLINs, pyrethroid- piperonyl butoxide LLINs; py- PPF- LLINs, pyrethroid- pyriproxyfen LLINs; 
s- LLINs, standard pyrethroid LLINs
 on M









pen: first published as 10.1136/bm





4 Mosha JF, et al. BMJ Open 2021;11:e046664. doi:10.1136/bmjopen-2020-046664
Open access 
cluster randomised trial with village hamlet as the unit of 
randomisation and repeated cross- sectional survey. The 
four study arms are:
 ► Mixture py- PPF- LLIN: Royal Guard (intervention 1).
 ► Mixture py- CFP- LLIN: Interceptor G2 (intervention 
2).
 ► Py- PBO- LLIN: Olyset Plus (intervention 3).
 ► S- LLIN: Interceptor (control arm).
The inhabitants of each cluster are blinded to the type 
of nets they received, as are the field staff who will collect 
entomological and clinical data. Nets of each type are 
similar in appearance apart from a colour- coded loop 
and a unique identifying number. Only the principal 
investigator and data manager know which code repre-
sents each intervention.
Mapping and cluster formation
Every building of 72 villages comprising 453 hamlets from 
17 wards was mapped using a global positioning system 
handheld unit (Garmin Legend e- trex) and ExpertGPS 
V.3.8 (TopoGrafix) software. A short Open Data Kit 
(ODK) programmed questionnaire, including name of 
the head of the household, number of people living in 
the house and number of children in each age group (6 
months–59 months, 5 years–10 years, 11 years –14 years) 
was recorded for each mapped household.
Wards to map were selected based on both malaria inci-
dence data collected from all health facilities in Misungwi, 
and Anopheles species composition (only areas with the 
main malaria vectors A. funestus s.s. and A. gambiae s.s 
were considered), assessed during pilot mosquito moni-
toring from all villages.
As in previous studies,8 clusters were designed with core 
and buffer areas to reduce the likelihood of spill- over of 
intervention effects from one cluster to another. Nets will 
be distributed to all households in a given cluster (ie, 
core and buffer areas), but monitoring of outcomes will 
be restricted to households situated in the cluster core. 
A total of 86 clusters were formed from the 72 villages 
(figure 3) using the spatial analyst toolbox in ArcGIS 
(ESRI, Redlands, the USA) based on the following 
criteria: no subdivision of village hamlets, minimum of 
150 households with children aged 6 months–14 years in 
the core area, and a minimum 600- metre buffer distance. 
The number of households in each cluster varied from 
172 to 2390 (urban area of Misungwi) with an average of 
492 households. A 600- metre buffer (ie, 600 m between 
the margins of core areas for any two adjacent clusters) 
was allocated thereby retaining 73.6% (31 125/42 314) 
of the households in the core area for sampling and data 
collection, with 134–828 core area households per cluster 
(figure 3C). Only two clusters did not meet the criteria 
of 150 households in the core area, and were therefore 
excluded.
Randomisation
After the completion of the baseline survey, covariate 
constrained randomisation was used to allocate the 84 
clusters across the four study arms. Covariate constrained 
allocation ensures that the arms are balanced overall by 
Figure 2 Trial study design. CDC, Centers for Disease Control and Prevention.
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excluding allocations where predetermined factors are 
not balanced within set margins.37 The following factors 
were constrained: baseline (preintervention) malaria 
infection prevalence in children aged 0.5–14 years, 
previous LLIN usage, socioeconomic status (SES), popu-
lation size, suitable conditions for A. gambiae s.s. and for A. 
funestus s.l. Suitability for each Anopheles species was deter-
mined using an ecological niche modelling approach 
(online supplemental file 1) as it was not possible to assess 
the species composition in all clusters before the rando-
misation. From among all possible allocations meeting 
the balancing constraints, one allocation was selected at 
random. The randomisation was performed by indepen-
dent statistician.
Interventions
In all four trial arms, net distribution was carried out in 
an identical manner by the Tanzania Communication and 
Development Center, a Tanzanian not- for- profit organi-
sation, and supervised by the NMCP to follow national 
net distribution campaign guidelines.38 All households, 
enumerated in the core and buffer area, were allocated 
one net for every two people as recommended by the 
Tanzania NMCP.38 Information, education and commu-
nication (IEC/SBCC) activities were conducted by a 
Tanzanian NGO, Tulonge Afia, before, during and after 
the net distribution to increase usage in the study area 
and supported by the US President Malaria Initiative. 
Householders were not asked to return their old net but 
to use the new net provided. To maximise effective LLIN 
coverage, two door- to- door hang- up campaigns were 
done after 2 weeks and again 3 months after distribution.
All nets distributed were blue and rectangular (180 
cm length×160 cm wide×180 cm high). They differed by 
study arm as described in the following sections.
Control
Interceptor LN (BASF Corporation, Germany) is a 
pyrethroid- only LLIN with alpha- cypermethrin at a target 
dose of 200 mg/m2, coated onto polyester filaments. 
Pyrethroids are neurotoxic insecticides, which target the 
nervous system of insects. Interceptor LN was chosen as a 
Figure 3 Study area. Map showing Misungwi study area in Mwanza region, North Tanzania (A), the 85 study clusters identified 
with core and buffer area and intervention allocation (B). (C) Closer map on the minimum 600 000 m area between houses in 
adjacent clusters.
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direct comparison to Interceptor G2 LN and Royal Guard 
LN, as they are all impregnated with the same pyrethroid 
(alpha- cypermethrin); some insecticide resistance mech-
anisms involving CYPs are specific to type I (permethrin) 
or type II (alpha- cypermethrin) pyrethroids.
Intervention 1
Royal Guard LN (Disease Control Technologies) is a 
mixture LLIN made of polyethylene incorporating 225 
mg/m2 PPF and 216 mg/m2 alpha- cypermethrin. PPF 
is known to disrupt female mosquito reproduction and 
fertility of eggs, stopping the production of the next 
generation of mosquitoes.39 PPF may be transferred 
by auto- dissemination; the transfer of small but toxic 
amounts of this highly potent insecticide on the tarsi 
(feet) of female mosquitoes to breeding sites where it can 
also act as a larvicide.40
Intervention 2
Interceptor G2 LN is a mixture LLIN made of polyester 
coated with a wash- resistant formulation of 200 mg/
m2 chlorfenapyr and 100 mg/m2 alpha- cypermethrin. 
Chlorfenapyr disrupts cellular respiration and oxidative 
phosphorylation in mitochondria, and due to this unique 
mode of action is toxic against mosquitoes that are resis-
tant to standard neurotoxic insecticides like pyrethroids.41
Intervention 3
Olyset Plus LN (Sumitomo Chemical) is a mixture LLIN 
combining PBO (400 mg/m2) and the repellent pyre-
throid permethrin (800 mg/m2) incorporated into poly-
ethylene fibres. PBO is a chemical synergist which acts by 
inhibiting mixed function oxidases, preventing detoxifi-
cation of the pyrethroid insecticide. Two RCTs demon-
strated that Olyset Plus LLINs were more effective than 
Olyset Net LN (the standard of care in Tanzania), in areas 
with pyrethroid resistance.8 12
Study outcomes
Primary outcomes
The primary outcomes (table 1) will be:
 ► Malaria infection (by mRDT) in children aged 6 
months–14 years old at 24 months postintervention.
 ► EIR as a measure for malaria transmission in the 
primary vector species.
 ► Cost- effectiveness of each of the four net types relative 
to one another.
Secondary outcomes
 ► Incidence of malaria cases in children aged 6 
months–10 years (measured over 24 months 
follow- up).
 ► Moderate and severe anaemia in children under 5 
years old (<8 g/dL) at 12, 18, 24, 30 and 36 months.
 ► Malaria infection (by mRDT) in children aged 6 
months–14 years at 12, 18, 30 and 36 months.
 ► Changes in frequency and intensity of phenotypic 
and genotypic resistance to pyrethroids (alpha- 
cypermethrin and permethrin), PBO, CFP and PPF.
 ► Other entomological outcomes: changes in mosquito 
resting behaviour indoors and outdoors, species 
composition and density ratio, host feeding, mosquito 
ovary development and fecundity.
 ► Incremental financial cost to the provider of each of 
the four net types relative to one another.
Data collection
Intervention coverage data
LLIN coverage will be evaluated 6 months after distribu-
tion and during each cross- sectional survey. Three indi-
cators will be used42: (1) ‘proportion of households with 
at least one LLIN for every two people (ownership)’, (2) 
‘proportion of household with enough LLINs to sleep 
under (access)’ and ‘proportion of households declaring 
using an LLIN (study or not) last night (usage)’.
Clinical data
To determine infection prevalence, repeated cross- 
sectional surveys will be conducted at 12, 18, 24, 30 and 
36 months after net distribution (table 1). At each time 
point, 45 households will be randomly selected from the 
core sampling area of each cluster, using the census list 
generated during baseline enumeration. In each house 
a maximum of two children, between 6 months and 14 
years old, will be selected. Accounting for households 
that are closed, refusing informed consent, or do not have 
children of the required age at the time of the survey, 
this sampling strategy is expected to yield an average of 
30 enrolled houses with 50 children per cluster based 
on previous studies.8 43 A total of 4200 children are thus 
expected to be surveyed at each time point.
Inclusion criteria are households with at least one child 
between 6 months and 14 years old who permanently 
resides in the selected household and an adult care-
giver who can provide written consent. Exclusion criteria 
include dwellings not found or vacant during the survey, 
no adult caregiver capable of giving informed consent, or 
eligible children are severely ill.
Information on sex, age distribution, educational status 
and occupation, SES, house structure, vector control 
measures used, past malaria cases, net coverage and 
care seeking behaviour will be collected. Fever or history 
of fever in the past 48 hours will be recorded for every 
child selected. Temperatures will be taken, and each 
child tested for malaria using mRDTs (CareStart RDTs; 
HRP2, (pf), DiaSys, Wokingham, UK) and haemoglobin 
levels measured (HemoCue Hb 201+ (Aktiebolaget Leo 
Diagnostics, USA)). When the mRDT is positive, free 
treatment for malaria will be provided with artemether- 
lumefantrine (artemisinin- based combination therapy; 
ACT), as per the national guidelines. Children with severe 
malaria or any other diseases that cannot be treated by 
the team will be referred to the nearest health facility.
To assess malaria case incidence, 35 children per cluster, 
aged 6 months–10 years old, will be randomly selected 
and followed up every 2 weeks during the high transmis-
sion season (October to July) and every month during the 
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low transmission season (August to September), over a 
12 months period (table 1). To reduce attrition, another 
cohort of children will be selected at the beginning of 
the second year and will also be followed for 12 months. 
All cohort children will be cleared of malaria infection at 
the beginning of the first and second year by ACT treat-
ment. Cohort children will then be checked 2 weeks later 
by mRDT and microscopy (if the mRDT is positive) to 
confirm whether they have been cleared. During each 
bi- weekly or monthly visit, children with fever ≥37.5°C 
and/or history of fever for the past 48 hours will be tested 
for the presence of malaria parasites (case incidence) by 
mRDT. For those with positive mRDT results, a blood slide 
will also be taken to confirm malaria positivity and they 
will also be treated, as previously described. Children will 
be encouraged to visit a health facility in case they have 
fever, or get sick at any time between visits. Each child will 
be provided with a personal medical book where malaria 
episodes will be recorded during study visits or whenever 
they attend a health facility and also will be provided with 
medical insurance. During cohort visits, a questionnaire 
will also be administered to inquire about net usage the 
night before the visit, any adverse events encountered 
and travel history within the past 2 weeks.
Entomological data
Cross- sectional entomological surveys will be carried 
out in 84 study clusters to monitor the indoor mosquito 
population density (table 1). Each cluster will be visited 
once every quarter; each month, seven clusters from each 
Table 1 Trial outcome measurements




Rapid diagnostic test Cross- sectional survey Baseline, 12, 18, 24, 30 and 36 
months postintervention
Anaemia Haematocrit Cross- sectional survey Baseline, 12, 18, 24, 30 and 36 
months postintervention
Temperature 1. Digital ear thermometer all 
children
2. Temperature and history of fever
1. Cross- sectional survey
2. Cohort follow- up
1. Baseline, 12, 18, 24, 30 and 36 
months postintervention
2. Every month
Malaria case Rapid diagnostic test taken when 
fever ≥37.5°C and or history of 
fever for the past 48 hours
Cohort follow- up Every 2 weeks during high 
transmission season (October to 
July) and every month during dry 
season (August to September)
Measurement of entomological outcomes
Indoor Anopheles density CDC light traps Entomology surveillance 8 houses per cluster every 3 
months in all clusters for 3 years
Outdoor biting Adapted Furvela tent trap55 Sentinel site Two times a year in 2–3 sentinel 
site per arm
Mosquito sporozoite rate CSP- ELISA to estimate EIR46 Entomology surveillance Subsample (30%) of the mosquito 
collected in CDC light trap
Anopheles species 
identification
1. A. funestus s.l. complex: 
conventional PCR or multiplex real 
time PCR49
2. A. gambiae s.l. complex: TaqMan 
real time PCR48
Entomology surveillance 
and Sentinel site and 
resistance test






Collection of adult 
Anopheles resting indoors
Once a year in a subsample of 
clusters
Frequency of Vgsc 
mutation
TaqMan PCR50 Entomology surveillance Subsample of mosquitoes 
collected in light trap
Insecticide resistance 
mechanisms
Multiplex TaqMan reverse- 
transcription quantitative PCR 
(RT- qPCR) will be used to monitor 
expression of CYPs and other 
metabolic enzymes known to be 
over- expressed in resistant A. 
gambiae s.s. and A. funestus s.s. 
populations from previous studies 
in Tanzania54
Collection of adult 
Anopheles resting 
indoors, previously 
phenotyped in resistance 
bioassays
At baseline and at each 
postintervention year in a 
subsample of clusters
CDC, Centers for Disease Control and Prevention; CSP, circumsporozoite protein; EIR, entomological inoculation rate.  on M
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study arm will be selected. Indoor mosquito densities 
will be monitored using Centers for Disease Control and 
Prevention (CDC) Miniature light traps (John W Hock 
Company, USA) in eight randomly selected households 
in the core area of each cluster. CDC light trap will be 
installed at the feet of one bed and existing net substi-
tuted with a project standard LLIN, and replaced the 
following day. For each of the selected houses, a short 
questionnaire will be administered to collect information 
about the number of inhabitants, type of house construc-
tion materials, presence of animals, coverage and usage 
of nets, and other malaria prevention measures used 
by household members. Sampled mosquitoes will be 
identified morphologically following the identification 
key by Gillies MT and Coetzee M. A supplement to the 
Anophelinae of Africa south of the Sahara (Afrotropical 
region), 1987.44 Parity rates will be estimated in a subset 
of live Anopheles mosquitoes through dissection.45 About 
10 A. gambiae s.l and 10 A. funestus s.l will be randomly 
picked per household per collection night and preserved 
for laboratory analysis. This sample of mosquito speci-
mens will be screened for Plasmodium falciparum circum-
sporozoite protein (Pf- CSP) by ELISA.46 The CSP- ELISA 
positive samples will be reanalysed by heating the ELISA 
lysates to remove any false positives.47
PCR TaqMan assays will be used to discriminate 
members of A. gambiae species complex,48 and members 
of the A. funestus group49 on a subsample of Anopheles 
collected. A sample of A. gambiae s.s. and A. arabiensis will 
be genotyped for the L1014F- kdr and L1014S- kdr muta-
tions, associated with pyrethroid and DDT resistance, 
using TaqMan PCR assays, following the protocol by Bass 
et al.50
Phenotypic resistance and resistance levels to alpha- 
cypermethrin, permethrin, PPF and chlorfenapyr, will be 
characterised at baseline and yearly postintervention, in 
all four study arms, using WHO cylinder and modified 
CDC bottle bioassays.51 52 The PBO synergist effect on wild 
female A. gambiae s.l. and A. funestus s.l. will be assessed 
using pre- exposure to PBO followed by permethrin 
resistance intensity assays. All knockdown/dead mosqui-
toes at 60 min and surviving 72 hours postexposure to 
insecticides will be stored individually in RNA later and 
preserved at −20°C for gene expression analysis. RNA will 
be extracted from pools of A. gambiae s.s. or A. funestus 
s.s and cDNA synthesised, according to standard proce-
dures. Relative expression of CYPs and other metabolic 
enzymes, previously identified as being over- expressed 
in resistant A. gambiae s.s. and A. funestus s.s. populations 
in Tanzania,53 will be measured using multiplex TaqMan 
RT- qPCR assays.54
Malaria vector abundance, species composition, 
feeding and resting behaviours (including biting time, 
host preference), and contribution to outdoor malaria 
transmission will be assessed at baseline and after imple-
mentation of the interventions to assess changes over 
time in 10 clusters per treatment arm. CDC light trap 
and adapted Furvela tent traps55 will be used for indoor 
and outdoor collection of free flying mosquitoes. Resting 
Anopheles will be collected using CDC prokopack aspira-
tors. Subsamples of Anopheles will be subjected to the same 
laboratory tests than routine collection. Additional infor-
mation about mosquito collection methods is available in 
online supplemental file 1.
Economic data
Data on resource use and unit costs will be collected from 
primary and secondary sources, including discussions with 
net manufacturers, donors and experts; review of project, 
donor and Ministry of Health records; trial survey data on 
care seeking behaviour; published literature; and WHO- 
CHOICE unit cost estimates.56 Data on health outcomes 
will include primary trial data on malaria incidence and 
anaemia, as well as secondary data on the age structure of 
malaria incidence and life expectancy.57 58
Sample size and power consideration
Malaria prevalence cross-sectional survey
The sample size was calculated using the method of Hayes 
and Bennett, taking into account the cluster- randomised 
design.59 For the primary outcome prevalence of infec-
tion at 24 months, we assumed a malaria prevalence in 
the reference arm of 40%, an average of 50 individuals 
per cluster and a coefficient of variation of 21%, based on 
recent surveys in a similar area.60 To achieve 80% power 
to detect a prevalence ratio of 0.72, that is, a 28% lower 
prevalence in at least one of the intervention arms versus 
the reference at Bonferroni- corrected significance level 
of 1.67%, we require 21 clusters per arm. This calcula-
tion is conservative as it does not account for the repeated 
malaria prevalence measures; thus, we anticipate being 
able to detect even smaller differences.
Incidence of malaria infection in children cohort
Sample size calculations for the secondary outcome 
(cumulative malaria incidence) were based on the 
method of Hayes and Bennett.59 Based on a previous 
study (Jacklin Mosha, personal communication), it was 
assumed that the mean number of malaria episodes per 
child per year in the reference arm was 0.85 (monthly 
event rate of 0.071) with a between- cluster coefficient of 
variation of 21%. With a cohort of 35 children per cluster 
(21 clusters per arm), and accounting for attrition of 30% 
over 24 months, we would achieve 80% power to detect 
a 23.6% relative reduction in malaria cases per child 
per year (risk ratio 0.764) between at least one interven-
tion arm relative to the reference arm, using a two- sided 
Bonferroni- corrected significance level of 1.67%. If the 
incidence in the reference arm is lower, at 0.5 episodes/
year, we will still have 80% power to detect a 26.1% rela-
tive reduction (relative risk 0.739).
Entomological survey for EIR estimation
Sample size calculations for the entomological survey 
were based on the method of Hayes and Bennett.59 It 
was assumed that the mean EIR (number of infectious 
bites per household per month) in the reference arm 
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was 1.76 with a between- cluster coefficient of variation 
of 40%, based on a previous study.8 With a sample of 
eight households per cluster and sampling each cluster 
every quarter we will have collections for 32 house- nights 
per cluster per year. With 21 clusters per arm the study 
would achieve 80% power to detect a 36% relative reduc-
tion in monthly EIR (relative risk 0.64) between at least 
one of the intervention arms relative to the reference 
using a Bonferroni- corrected significance level of 1.67%. 
Changes in insecticide resistance frequency and resis-
tance management potential will be assessed separately 
from light trap and household resting collections.
Data management
Clinical and entomological measurements in the cohort 
study and the cross- sectional surveys will be captured on 
electronic forms using tablets/smartphones installed 
with ODK and uploaded daily onto the server at London 
School Hygiene and Tropical Medicine (LSHTM). Other 
data and clinical measurements during the cross- sectional 
survey, recorded on paper, will be double- entered into an 
access database independently by two data clerks. Labo-
ratory data outputs will be available directly from the 
analyser (eg, ELISA data) and imported into a database. 
All databases will maintain an audit trail with time- date 
stamps of data entry and all changes that are made to the 




Prevalence of malaria infection and EIR
The primary analysis will be conducted using the inten-
tion to treat (ITT) approach. Secondary per- protocol 
analyses will also be conducted. The primary outcome, 
measured at 12, 18, 24, 30 and 36 months after net 
distribution, will be analysed using mixed effects logistic 
regression. The unit of analysis will be the individual. The 
model will include fixed effects for time, study arm, and 
time by study arm, and will adjust for the baseline prev-
alence in each community as a covariate, as well as the 
covariates used in the covariate- constrained allocation 
procedure. The model will account for within- period and 
between- period intra- cluster correlations.61
Prevalence of malaria infection in each dual- AI LLIN 
treatment arm will be compared with the prevalence of 
infection in the reference arm using least square mean 
differences to assess whether the new LLINs are supe-
rior. The primary comparison will occur at the end of 
the 24 months postintervention period. To adjust for the 
increased risk of a type I error due to multiple pairwise 
comparisons, the level of significance will be adjusted 
using the Bonferroni method. Least square mean differ-
ences between each intervention arm versus control will 
be calculated at each time, together with 98.23% CIs 
(reflecting adjustment of usual 95% CI to account for 
multiple comparisons). Secondary analyses will include 
all possible pairwise comparisons of dual- AI LLIN arms.62 
Subgroup analyses will be performed to investigate the 
impacts of interventions according to different individual 
(ie, age, sex), household (ie, wealth, distance to health 
facilities) and cluster- level (ie, vector resistance intensity, 
vector species composition) characteristics.
EIR will be estimated as the mean number of sporo-
zoite infected mosquitoes per house per night (by species 
and overall) and weighted to account for proportion 
of mosquitoes processed for sporozoites. Differences in 
Anopheles density and EIR between the different arms 
will be estimated using random effects negative binomial 
regression taking into account the intracluster correla-
tion. Random effects logistic regression will be used to 
compare sporozoite rate between study arms.
Economic evaluation
Following relevant guidelines,63 64 we will combine 
primary trial data with secondary data in a decision 
analytic model using a decision tree. We will adopt a soci-
etal perspective, presenting costs both combined and 
disaggregated by payer, and model effects and costs over 
a lifetime horizon. In the main analysis, we will assume 
that nets are distributed in mass campaigns every 3 years, 
reflecting both what was done in the trial and standard 
practice in malaria control.
Effects will be presented as disability- adjusted life years 
(DALYs) discounted at 3% and with no age weighting, 
calculated as the sum of years of life with disability from 
malaria- related illness (uncomplicated and severe malaria 
cases and anaemia) and years of life lost from malaria 
deaths.63 The number of cases associated with each inter-
vention will be modelled as the product of the incidence 
in the reference arm, the incidence rate ratio of the rele-
vant arm to the reference arm, and a standardised popu-
lation size. Incidence in children aged 6 months–10 years 
will reflect ITT trial data, while incidence in other age 
groups, which comprise a small share of overall cases and 
deaths, will be estimated as a function of the incidence 
in children based on publicly available modelling.58 65 
DALYs will be calculated as the product of the estimated 
number of malaria cases (as earlier), the case fatality 
rate, and the remaining life expectancy at age of death. 
Rates of progression to severe disease and to death will 
be estimated to reflect real- world outcomes based on 
secondary data. In the main analysis (based on trial data 
at 24 months), possible bounds for incidence rate ratios 
over months 25–36 will be estimated based on annual 
rate ratios over 0–12 and 13–24 months and assuming no 
relative effect compared with s- LLINs. In additional anal-
yses, effects will also be presented as malaria cases and 
percentage point reduction in malaria prevalence.
We will plot the costs and effects of each intervention on 
the cost- effectiveness plane, identify the cost- effectiveness 
frontier and expansion path, and calculate incremental 
cost- effectiveness ratios between adjacent points on this 
path. Deterministic and probabilistic sensitivity anal-
ysis will explore the impact of uncertainty and hetero-
geneity on cost- effectiveness results. Cost- effectiveness 
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acceptability curves66 will indicate the probability of each 
strategy being the most cost- effective choice at plausible 
cost- effectiveness thresholds.67 68 Affordability will be 
explored by comparing additional financial costs (net of 
cost savings) per person to relevant expenditure levels. 




Cumulative incidence of malaria infection over the 24 
months follow- up (accounting for repeat episodes in the 
same child but measured on separate cohorts at 12 and 
24 months postintervention) will be analysed using mixed 
effects Poisson or negative binomial regression. The 
model will include fixed effects for time, study arm, and 
time by study arm, and will adjust for the covariates used 
in the covariate- constrained allocation procedure. The 
model will account for within- period and between- period 
intra- cluster correlations. Least square mean differences 
will be obtained from the model to compare each inter-
vention versus the control. Follow- up within 14 days of a 
previous episode in the same child will be censored and 
will not be included in the analysis. An offset for duration 
of follow- up will be included in the model to account for 
attrition.
Prevalence of anaemia
Prevalence of moderate and severe anaemia in children 
under 5 at 12,18, 24, 30 and 36 months will be analysed 
using mixed effects logistic regression similar to the 
approach outlined for malaria prevalence.
Insecticide resistance monitoring
Bioassay data will be interpreted according to the 
updated WHO guidelines: mortality of ≥98% indi-
cates susceptibility at the diagnostic dose, mortality of 
90%–97% is suggestive of resistance, and mortality of less 
than 90% indicates resistance.69 For resistance intensity 
assays at 5X insecticide concentrations, mortality ≥98% 
indicates low intensity resistance and mortality <98% 
indicates moderate to high intensity resistance. For resis-
tance intensity assays at 10X insecticide concentrations, 
mortality ≥98% indicates moderate intensity resistance 
and mortality <98% indicates high intensity resistance.
For metabolic gene assays, relative expression level and 
fold change of each target gene from resistant and suscep-
tible field samples, relative to the susceptible laboratory 
strain (A. gambiae s.s Kisumu or A. funestus s.s FANG), will 
be calculated using the 2−ΔΔCT method, incorporating 
PCR efficiency and normalised relative to the endoge-
nous housekeeping control gene.70
Patient and public involvement
There was no patient or public involvement in the design 
of this study. Communities will be involved in the imple-
mentation of the interventions and study activities through 
their leaders and community health representatives.
Ethics approval
This protocol has been reviewed and approved by all insti-
tutional review boards, including: the Medical Research 
Coordinating Committee of the National Institute 
for Medical Research, LSHTM, Kilimanjaro Christian 
Medical University College and University of Ottawa.
This study will be conducted according to the Decla-
ration of Helsinki and the International Guidelines for 
Ethical Review of Epidemiological Studies. All field and 
clinical staff as well as the principal investigator will 
receive training on good clinical and laboratory prac-
tice before data collection begins, and refresher training 
every year. For all data collection activities (epidemio-
logical and entomological), written informed consent 
(online supplemental file 2) will be obtained from an 
adult guardian in the household. The consent form will 
be written in Swahili and indicate the purpose of the 
study, the procedures, risks and benefits, that participa-
tion is completely voluntary, and that they may withdraw 
at any time with impunity. The study questionnaire will 
also be administered in Swahili.
Dissemination
Study findings will be shared in stakeholder meetings 
attended by local community leaders, the Ministry of 
Health, Community Development, Gender, Elderly and 
Children, the National Malaria Control Programme, 
the President’s office regional administration and local 
government representatives. Results will also be shared 
through peer- reviewed publications, at scientific confer-
ences, and through  clinicaltrials. gov.
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Protocol for a four parallel-arm, single-blind, cluster-randomized 
trial to assess the effectiveness of three types of dual active 
ingredient treated nets compared to pyrethroid-only long-lasting 
insecticidal nets to prevent malaria transmitted by pyrethroid 




Ecological niche modelling 
Suitability for each Anopheles species was determined using an ecological niche modelling approach, 
based on a maximum entropy (MaxEnt v.3.4.1) algorithm, similar to the approach described by 
Kulkarni et al. [1]. MaxEnt uses presence-only occurrence data in conjunction with environmental data 
to predict the potential distribution of a species across a defined landscape. Models were constructed 
for each major local species (An. gambiae s.s., An. arabiensis and An. funestus s.l.) using occurrence 
records from pilot mosquito monitoring alongside bioclimatic variables at a 1-km resolution from the 
WorldClim database (www.worldclim.org), including: temperature seasonality, annual precipitation, 
precipitation of wettest month, precipitation of driest month, and precipitation seasonality; and elevation 
from the Shuttle Radar Topography Mission (SRTM). To discriminate between sibling species of the 
An. gambiae s.l. complex, point locations where only An. gambiae s.s. (i.e. no An. arabiensis) was 
detected (n=12) were used as occurrence records. Point locations where >50% of the Anopheles 
mosquitoes were identified as An. funestus s.l. (n=51) were used as occurrence records for this species. 
Data were randomly partitioned for model evaluation, with 75% of the records used as training data to 
construct the models and the remaining 25% set aside for testing. The accuracy of each model was 
determined by performing both a threshold-dependent binomial test of omission and a threshold-
independent receiver operating characteristic analysis; models with an area under the curve (AUC) >0.8 
were retained, and the model with the highest AUC value for each species was used for subsequent 
analysis. The mean probability of suitability for each cluster was calculated using zonal statistics in 
ArcGIS. 
Entomological data collection 
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Routine entomology collection 
 Cross-sectional entomological surveys will be carried out in 84 study clusters to monitor the indoor 
mosquito population density. Each cluster will be visited once every quarter; each month, 7 clusters 
from each study arm will be selected. Indoor mosquito densities will be monitored using Centers for 
Disease Control and Prevention (CDC) Miniature light traps (John W Hock Company, USA) in 8 
randomly selected households in each of the cluster core areas. During the collection night, the owner’s 
bed net in the bed/sleeping place where the CDC light trap will be installed will be substituted with a 
project standard LLIN, and replaced the following day. For each of the selected houses, a short 
questionnaire will be administered to collect information about the number of inhabitants, type of house 
construction materials, presence of animals, where the animals are kept, coverage and usage of study 
nets and other net types found, and other malaria prevention measures used by household members. 
Sampled mosquitoes will be identified morphologically following the identification key by Gillies and 
Coetzee [2]. Physiological status of Anopheles mosquitoes (blood-fed, unfed, gravid, semi-gravid) will 
be recorded.  Parity rates will be estimated in a subset of live Anopheles mosquitoes through dissection 
[3]. Maximum 10 An. gambiae s.l and 10 An. funestus s.l will be randomly picked per household per 
collection night and preserved for molecular analysis. The mosquito specimens will be screened for 
Plasmodium falciparum circumsporozoite protein (Pf-CSP) by ELISA [4]. The CSP-ELISA positive 
samples will be re-analysed by heating the ELISA lysates to remove any false positives [5].      
All specimens positive for Pf-CSP, as well as a subsample of CSP negative of An. gambiae s.l. and An. 
funestus s.l from each cluster per survey round, will be analysed for sibling species identification. PCR 
TaqMan assays will be used to discriminate members of An. gambiae species complex [6], and members 
of  the An. funestus group [7]. A subsample of An. gambiae s.s. and An. arabiensis  that are screened 
for malaria sporozoites infection will be genotyped for the L1014F-kdr and L1014S-kdr mutations, 
associated with pyrethroid and DDT resistance, using TaqMan PCR assays, following the protocol by 
Bass et al [8].   
Insecticide resistance monitoring 
Phenotypic resistance and resistance levels to alpha-cypermethrin, permethrin,  and chlorfenapyr, will 
be characterized at baseline and yearly post-intervention, in all four study arms, using WHO cylinder 
and modified CDC bottle bioassays [9, 10]. The PBO synergist effect on wild female An. gambiae s.l. 
and An. funestus s.l. will be assessed using pre-exposure of PBO in CDC bottles followed by permethrin 
resistance intensity assays. The effect of PPF on fertility/egg development in adult female Anopheles, 
after 72 hours post-exposure to PPF using CDC bottle bioassays, will be assessed by ovarian dissection 
under a light microscope [11]. The developmental status of ovarian follicles/eggs will be classified as 
fertile or infertile and interpreted following the Christopher’s stages of egg development [12, 13]. All 
assays will be performed using wild, indoor resting mosquitoes collected from house walls using 
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Prokopack and manual aspirators. Mosquitoes will be held for three days, fed on 10% glucose solution, 
to allow for blood-meal digestion, prior to bioassay testing. Mosquitoes will be morphologically 
identified as An. gambiae s.l. or An. funestus s.l. [2], and species complexes will be tested separately 
[6, 7].  All knockdown/dead mosquitoes at 60 minutes and surviving 72 hours post-exposure to 
insecticides will be stored individually in RNAlater® and preserved at -20°C for gene expression 
analysis. Per mosquito, 4-6 legs will be removed to identify individuals to species-level using TaqMan 
PCR [34-36]; only PCR-confirmed An. gambiae s.s. or An. funestus s.s., will be pooled separately for 
further analysis. RNA will be extracted from pools of An. gambiae s.s. or An. funestus s.s and cDNA 
synthesized, according to standard procedures. Relative expression of CYPs and other metabolic 
enzymes, previously identified as being over-expressed in resistant An. gambiae s.s. and An. funestus 
s.s. populations in Tanzania [14], will be measured using multiplex TaqMan RT-qPCR assays [15].   
Mosquito behaviour 
Malaria vector abundance, species composition, feeding and resting behaviours (including biting time, 
host preference), and contribution to outdoor malaria transmission will be assessed at baseline and after 
implementation of the interventions to assess changes over time. These mosquito behavioural 
adaptations will be assessed twice a year during the high mosquito density seasons (April-May and 
October-November)using CDC light traps indoor, occupied adapted Furvela tent traps outdoors [16] 
and indoor and outdoor resting collection using Prokopack aspirators. Collections will be done in 2 
houses in 40 sentinel clusters (10 clusters per treatment arm) selected for their had high density of 
mosquitoes. In each household, light traps will be set up inside and one tent installed outside, close to 
the house. In the house were the mosquito traps will be installed, indoor resting mosquito collections 
will be conducted on the walls, roofs, and inside the nets. Similarly, outdoor collections of resting 
mosquitoes will be performed in potential resting sites around the house, such as open resting structures, 
cow sheds and pit latrines. A sub-sample of An. gambiae s.l. and An. funestus s.l. per each collection 
method will be tested for the presence of Pf-CSP [4] and identified to sibling species level [6, 7]. All 
freshly collected blood-fed Anopheles mosquitoes will be screened for the blood meal sources[17] . 
 The sterilizing effect of py-PPF ITN (Royal Guard®) relative to the standard LLINs on egg 
development in female wild malaria vectors will be assessed. This study will be conducted once a year 
in 10 sentinel clusters receiving Royal Guard, and 10 sentinel clusters receiving the standard LLIN. 10 
houses per cluster will be visited, and sampled for freshly blood fed mosquitoes resting on the wall or 
inside the nets. Anopheles will be supplied with 10% glucose solution, monitored for survival and 
dissected 72 hours after collection to look at the developmental stages of eggs as a proxy of fertility 
[11]. Gravid alive females will be anesthetized at −20°C for 8–10 min and individually dissected in a 
drop of distilled water by gently pulling out the last two segments, 7th and 8th sternites of the mosquito 
abdomen. 
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ANNEXE: Consent forms (English) 
 
1 Consent forms: Household and prevalence survey  
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Introduction   
Good morning.  My name is _______________________________________.  I work with PAMVERC Malaria 
Prevention Trial Missungwi.  We work together with the Missungwi District Health office, the National 
Institute for Medical Research, the Kilimanjaro Christian Medical College, London School of Hygiene and 
Tropical Medicine. I am here to ask you some questions and do some simple tests to learn how well malaria 
prevention and treatment are working in Missungwi. To do this, we are gathering information by visiting a 
number of households in your community. 
Purpose of the survey 
To see if the malaria program works, we would like to ask you some general questions about your household, 
bed-net possession, and use. We want to see how common malaria is among people in your community by 
testing for parasites in their blood. Your responses to our questions and the results of our studies will help 
us learn how best to further improve malaria control in your community and in the country.  
Procedures 
• If you agree to take part, we will ask you a number of questions about your family and household about 
bed nets used. Some people will be selected to be tested for malaria. I will ask all selected people to go 
to see a PAMVERC-employed nurse on the ____________ (give the date of the consultation) in 
_____________ (give the place). The nurse will take several small drops of blood from each selected 
person. The whole process should take about 30 minutes. 
• The nurse will take a small amount of blood from the finger using a small needle. One drop of blood will 
be used to test for a rapid malaria diagnostic test, and other drop to prepare the blood slide. This blood 
slide will be analysed in a laboratory in KCMC and may need to be kept for further analysis after the 
survey. A drop of blood will also be used to test for anaemia. The identity of the person will not be 
connected to these samples.  We will also test whether the person currently has fever. 
• The results from the malaria rapid diagnostic test will be given the same day. If the person has malaria 
or fever, he will be provided with free drugs by the PAMVERC clinician. In case the person does not get 
better, you are requested to go to the nearest health facility immediately to receive alternative treatment 
according to the Ministry of Health policies. If we diagnose any person as having severe malaria or other 
diseases you will be immediately referred to nearby health facilities. 
• Net inspection: If you agree to take part in this survey, we will ask you additional questions about the net 
you have (washing, type of sleeping bed and repair) and would like also to see and inspect two nets in 
your house to assess the quality. This will help us determine for how long these nets can sustain different 
field condition. Therefore, enable us devise alternative measures for improving and strengthening nets 
to meet community needs. I will not damage the net, and after the interview and will return it after the 
inspection. 
Risks and Benefits 
The tested person will feel pain for a few seconds when we take the blood from his/her finger. If the test 
shows that your child has malaria, or fever at the time of the survey, they will receive free treatment that the 
Ministry of Health recommends. These drugs are proven to be safe and effective, but any drugs can cause 
side effects in a small number of patients. The nurse will discuss if treatment is needed. 
Voluntariness and confidentiality 
It is entirely your choice to take part in or not take part in this survey as I have just described it. If you do 
agree to take part, your individual answers to all questions and the test results will be kept private and not 
revealed to anyone. If you agree to take part, you can also decide not to answer any of the questions that 
you do not want to, and you can refuse the blood tests.   
Costs and compensation for participating in the study 
You will not be asked to pay anything for you to participate in this study. The study will not reimburse you 
with any payment for taking part in the study. 
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Consent for long-term sample storage for future studies 
We are also asking people who join this study if they will let the researchers’ use their blood sample for future 
studies. These future studies may help find new ways to prevent malaria or other diseases. If you agree, we 
will store your blood in the laboratory with a unique number and not with your name. Your sample will be 
stored for up to 25 years. We may share your test results with researchers at other organizations but we will 
not give them your name, address, or any information that could identify you. After the study has ended, we 
will remove any means to link the sample to you, and we will not be able to find your sample. If you do not 
wish to have your blood stored for future tests, you may still participate in our study. 
 
The London School of Hygiene and Tropical Medicine is the Sponsor and hold insurance policies which apply 
to this study 
 
 
Thank you very much for your time.  Would you like to take part in this survey? 
 
 
HOUSEHOLD COPY – Household and child – Date: ___/___/___ 
Consent 
• The study has been explained to me, I have been given the opportunity to ask questions concerning 
this study. Any such questions have been answered to my full satisfaction.  I understand participation 
is voluntary and I may revoke this consent at any time without penalty or loss of benefits, if any. 
• I agree for me and my child/children to take part. 
• I agree that the data generated from this study can be used in the future for other malaria related 
research.  Yes  |___|    No    |___| 
I agree that the dried blood samples stored can be used in the future for other malaria related 
research. Yes  |___|    No    |___| 
Name of participant.................................……….............. Signature/Thumb print ................................... 
Relationship to the children………………………………………….….. 
Name of the witness.....................................................Signature……………………....................................... 
Name of interviewer……………………….............................Signature............................................................ 
 
If you have any questions or clarification pertaining to this survey please feel free to ask the field workers 
and nurse or you may contact Mr Eliud Lukole, PAMVERC, 0766240101; Dr Jackline Mosha, NIMR Mwnza, 
0754404140; Dr Alphaxard Manjurano, 0756026661. 
If you have any questions about your rights as a study patient, or if you think your child has been injured 
because of this study, please contact the Chairman of the National Health Research Ethics Committee 
(NatHREC) on 0222 121 400/390 
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PROJECT COPY – Household and child 
Date: ___/____/_____        Cluster Number: ___ ___ Household Number: ___ ___ ___  
 MALARIA PREVALENCE SURVEY INFORMED CONSENT AGREEMENT FOR THE PARENT / 
GUARDIAN OF CHILDREN IN THE TRIAL 
 
Consent 
• The study has been explained to me, I have been given the opportunity to ask questions concerning 
this study. Any such questions have been answered to my full satisfaction.  I understand participation 
is voluntary and I may revoke this consent at any time without penalty or loss of benefits, if any. 
• I agree for me and my child/children to take part. 
• I agree that the data generated from this study can be used in the future for other malaria related 
research.  Yes   |___|    No    |___| 
I agree that the dried blood samples stored can be used in the future for other malaria related 
research. Yes  |___|    No    |___| 
Name of participant.................................……….............. Signature/Thumb print ..................... 
Relationship to the children…………………………………………….….. 
Name of the witness.....................................................Signature……………………....................................... 
Name of interviewer……………………….............................Signature............................................................ 
 
If you have any questions or clarification pertaining to this survey please feel free to ask the field workers 
and nurse or you may contact Mr Eliud Lukole, PAMVERC, 0766240101; Dr Jackline Mosha, NIMR Mwnza, 
0754404140 and Dr Alphaxard Manjurano, 0756026661. 
If you have any questions about your rights as a study patient, or if you think your child has been injured 
because of this study, please contact the Chairman of the National Health Research Ethics Committee 
(NatHREC) on 0222 121 400/390 
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2 Consent forms: Children cohort follow up 
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CHILDREN COHORT FOLLOW UP CONSENT FORM 
Introduction   
 
Good morning.  My name is _______________________________________.  I work with PAMVERC Malaria 
Prevention Trial Missungwi.  We work together with the Missungwi District Health office, the National 
Institute for Medical Research, the Kilimanjaro Christian Medical College, London School of Hygiene and 
Tropical Medicine. I am here to ask you some questions and do some simple tests to learn how well malaria 
prevention is working in Missungwi.  
Purpose of the survey 
To see if the mosquito net distributed works. We want to know if children in your community have malaria 
by taking their temperature and testing for parasites in their blood if they feel unwell. Your responses to our 
questions and the results of our studies will help us learn how best to further improve malaria control in your 




If you agree to take part, we will select at random one children from 6 months to 10 years from your 
household to attend every month the PAMVERC mobile clinic located in your hamlet or a nearby hamlet. We 
will ask you some questions about the child, including if he had fever, if he is sick and received a treatment, 
bed-net use and any side effect from the use of bed net. We will take his temperature. If your child has 
symptoms of malaria infection the nurse will take several small drops of blood to diagnose malaria. The whole 
process should take about 30 minutes. The selected child will be followed for one year or until he/she reach 
10 years old. 
 
To diagnose malaria, the nurse will take a small amount of blood from the finger using a small needle. One 
drop of blood will be used to test for a rapid malaria diagnostic test. The identity of the child will not be 
connected to these samples. 
 
The results from the malaria rapid diagnostic test will be given the same day. If the person has malaria or 
fever, he will be provided with free drugs by the PAMVERC clinician. In case the person does not get better, 
you are requested to go to the nearest health facility immediately to receive alternative treatment according 
to the Ministry of Health policies. If we diagnose any person with severe malaria or other diseases, you will 
be immediately referred to nearby health facilities. 
 
Risks and Benefits 
The tested person will feel pain for a few seconds when we take the blood from his/her finger. If the test 
shows that your child has malaria, or fever at the time of the survey, they will receive free treatment that the 
Ministry of Health recommends. These drugs are proven to be safe and effective, but any drugs can cause 
side effects in a small number of patients. The nurse will discuss if a treatment is needed. 
 
Voluntariness and confidentiality 
It is entirely your choice to take part or not in this survey as I have just described it. If you do agree to take 
part, your individual answers to all questions and the test results will be kept private and not revealed to 
anyone. If you agree to take part, you can decide not to answer some of the questions, and you can also 
refuse the blood tests.   
 
Costs and compensation for being in the study 
You will not be asked to pay anything for you to participate in this study. You will receive reimbursement for 
your transport to come to the mobile clinic and go back home. The total amount will be on average 2,000Tsh 
for each visit. 
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Consent for long-term sample storage for future studies 
We are also asking people who join this study if they will let the researchers’ use their blood sample for future 
studies. These future studies may help find new ways to prevent malaria or other diseases. If you agree, we 
will store your blood in the laboratory with a unique number and not with your name. Your sample will be 
stored for up to 25 years. We may share your test results with researchers at other organizations but we will 
not give them your name, address, or any information that could identify you. After the study has ended, we 
will remove any means to link the sample to you, and we will not be able to find your sample. If you do not 
wish to have your blood stored for future tests, you may still participate in our study. 
 
The London School of Hygiene and Tropical Medicine is the Sponsor and hold insurance policies which apply 
to this study 
 
Thank you very much for your time.  Would you like to take part in this survey? 
 
 




• The study has been explained to me, I have been given the opportunity to ask questions concerning 
this study. Any such questions have been answered to my full satisfaction.  I understand participation 
is voluntary and I may revoke this consent at any time without penalty or loss of benefits, if any. 
• I agree for me and my child/children to take part. 
•  I agree that the data generated from this study can be used in the future for other malaria related 
research.  Yes  |___|    No    |___| 
• I agree that the dried blood samples stored can be used in the future for other malaria related 
research. Yes  |___|    No    |___| 
Name of guardian/parent.................................……….............. Signature/Thumb print ...................... 
Name of the child selected……………………………………Relationship to the chil…….…………………………………… 
Name of the witness.....................................................Signature……………………....................................... 
Name of interviewer……………………….............................Signature............................................................ 
 
If you have any questions or clarification pertaining to this survey please feel free to ask the field workers 
and nurse or you may contact Mr Eliud Lukole, PAMVERC, 0766240101; Dr Jackline Mosha, NIMR Mwnza, 
0754404140; Dr Alphaxard Manjurano, 0756026661;  
If you have any questions about your rights as a study patient, or if you think your child has been injured 
because of this study, please contact the Chairman of the National Health Research Ethics Committee 
(NatHREC) on 0222 121 400/390] 
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PROJECT COPY – Household and child 
Date: ___/____/_____        Cluster Number: ___ ___ Household Number: ___ ___ ___  
 CHILDREN COHORT FOLLOW UP CONSENT FORM 
 
CONSENT 
• The study has been explained to me, I have been given the opportunity to ask questions concerning 
this study. Any such questions have been answered to my full satisfaction.  I understand participation 
is voluntary and I may revoke this consent at any time without penalty or loss of benefits, if any. 
• I agree for me and my child/children to take part. 
• I agree that the data generated from this study can be used in the future for other malaria related 
research.  Yes  |___|    No    |___| 
I agree that the dried blood samples stored can be used in the future for other malaria related research. Yes  
|___|    No    |___| 
Name of guardian/parent.................................……….............. Signature/Thumb print .............................. 
Name of the child selected……………………………………Relationship to the child…….…………………………………… 
Name of the witness.....................................................Signature……………………....................................... 
Name of interviewer……………………….............................Signature............................................................ 
 
If you have any questions or clarification pertaining to this survey please feel free to ask the field workers 
and nurse or you may contact Study staff; Mr Eliud Lukole, PAMVERC, 0766240101; Dr Jackline Mosha, 
NIMR Mwnza, 0754404140; Dr Alphaxard Manjurano, 0756026661; 
If you have any questions about your rights as a study patient, or if you think your child has been injured 
because of this study, please contact the Chairman of the National Health Research Ethics Committee 
(NatHREC) on 0222 121 400/390] 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
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3 Consent forms: Mosquito trapping  
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Introduction   
Good morning.  My name is __________.  I work with PAMVERC Malaria Prevention Trial in Missungwi.  We 
work together with the Missungwi District Health office, the National Institute for Medical Research, the 
Kilimanjaro Christian Medical College, London School of Hygiene and Tropical Medicine.  
Purpose of the survey 
We would like to include you in a study to find out if different new nets products as one of the control 
intervention can reduce the transmission of malaria in your communities. Malaria is transmitted by 
mosquitoes that carry the malaria parasite. The control interventions reduce the number of infected 
mosquitoes. We want to find out whether the LLINs reduce the number of mosquitoes flying into your 
house. It will provide information on which new LLINs works best to reduce mosquito numbers and malaria. 
Procedure for light trap catching 
 If you agree to participate, we will carry out the following activities: 
1. Collection of mosquitoes using a special light trap in your bedroom for one night. The trap will 
collect mosquitoes coming indoors and we will collect the trap early the following morning. The 
trap light will be turned on in the early evening and will be on through the night. You and others in 
the room will sleep under a bed net which we will provide for you, and for the others if necessary, 
on the night we collect mosquitoes. 
2. You will be asked to complete a short questionnaire. We will ask a few questions about your house 
and any mosquito control you may have used. For this process you will be identified by a study 
code, not by your name, so that the views you express and answers you provide will remain 
completely anonymous. 
 
Procedure for tent trap collection 
 If you agree to participate, we will carry out the following activities: 
1. Collection of mosquitoes using a special trap that will be set up outside your house. The trap will 
collect outdoors mosquitoes. We will ask you permission to install a tent nearby your houses and 
allow us to sleep under. 
2. You will be asked to complete a short questionnaire. We will ask a few questions about your house 
and any mosquito control you may have used. For this process you will be identified by a study 
code, not by your name, so that the views you express and answers you provide will remain 
completely anonymous. 
 
Procedure for collection of resting mosquitoes 
1. We will collect mosquitoes resting on your wall and inside your net early on the morning around 6-
7 am. 
2. For this process your house will be identified by a study code, so that the result cannot be related 
to you 
 
Voluntariness and confidentiality 
It is entirely your choice to take part in or not take part in this survey as I have just described it. If you agree 
to take part, you can also decide not to answer any of the questions that you do not want to.  Your 
individual information will be kept private.  
Risks and Benefits:  
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We can see no risk in taking part in this study. If you are not sleeping under a long-lasting Net you will receive 
one to sleep under the night the trap is running. The traps may reduce the number of mosquitoes in your 
house. The results of the study will help us learn how best malaria can be controlled.   
Costs and compensation for participating in the study 
You will not be asked to pay anything for you to participate in this study. The study will not reimburse you 
with any payment for taking part in the study. 
The London School of Hygiene and Tropical Medicine is the Sponsor and hold insurance policies which apply 
to this study 
 
 
Thank you very much for your time.  Would you like to take part in this survey? 
 
HOUSEHOLD COPY             Date: _____/______/________ 
Mosquito trapping Informed Consent agreement  
 
Consent section 
• The study has been explained to me, I have been given the opportunity to ask questions concerning 
this study. Any such questions have been answered to my full satisfaction.  I understand participation 
is voluntary and I may revoke this consent at any time without penalty or loss of benefits, if any. 
• I agree to take part to the survey 
•  I also agree that the data generated from this study and the dried blood samples stored can be used 
in the future for other malaria related research.  
  
Name of guardian/parent.................................……….............. Signature/Thumb print .............................. 
Name of the witness.....................................................Signature……………………....................................... 
Name of interviewer……………………….............................Signature............................................................ 
  
If you have any questions or clarification pertaining to this survey please feel free to ask the field workers 
or you may contact Mr Eliud Lukole, PAMVERC, 0766240101; Dr Jackline Mosha, NIMR Mwnza, 
0754404140; Dr Alphaxard Manjurano, 0756026661. 
If you have any questions about your rights as a study patient, or if you think your child has been injured 
because of this study, please contact the Chairman of the National Health Research Ethics Committee 
(NatHREC) on 0222 121 400/390 
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PROJECT COPY        Date _____/______/______ 
Cluster Number: ___ ___Household Number: ___ ___ ___  Round: __ __ 
Mosquito trapping Informed Consent agreement  
 
Consent section 
The study has been explained to me, I have been given the opportunity to ask questions concerning this 
study. Any such questions have been answered to my full satisfaction.  I understand participation is voluntary 
and I may revoke this consent at any time without penalty or loss of benefits, if any. 
 
 I agree to take part. 
 
Name of guardian/parent.................................……….............. Signature/Thumb print .............................. 
Name of the witness.....................................................Signature……………………....................................... 
Name of interviewer……………………….............................Signature............................................................ 
  
 
If you have any questions or clarification pertaining to this survey please feel free to ask the field workers 
or you may contact Mr Eliud Lukole, PAMVERC, 0766240101; Dr Jackline Mosha, NIMR Mwnza, 
0754404140; Dr Alphaxard Manjurano, 0756026661 
If you have any questions about your rights as a study patient, or if you think your child has been injured 
because of this study, please contact the Chairman of the National Health Research Ethics Committee 
(NatHREC) on 0222 121 400/390 
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